Caris Life Sciences, Inc. (CAI)

Market Cap	4.38B
Revenue (ttm)	907.29M +100.5%
Net Income	-411.42M
EPS	-1.80
Shares Out	282.68M
PE Ratio	n/a
Forward PE	78.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,970
Open	15.48
Previous Close	15.52
Day's Range	15.39 - 15.55
52-Week Range	14.19 - 42.50
Beta	n/a
Analysts	Strong Buy
Price Target	28.00 (+80.53%)
Earnings Date	May 7, 2026

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2025
• Employees: 1,846
• Stock Exchange: NASDAQ
• Ticker Symbol: CAI
• Website: https://www.carislifesciences.com

Financial Performance

In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.

Analyst Summary

According to 13 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $28.0, which is an increase of 80.53% from the latest price.

Price Target

$28.0

(80.53% upside)

Analyst Consensus: Strong Buy